Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...
MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
Medpage Today on MSN2d
New APA President-Elect; Novel Depression Drug Flops; Probiotics and SchizophreniaInvestigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback